[1]李进 狄红杰 刘超.慢性肾脏疾病和睾酮的相关性[J].国际内分泌代谢杂志,2018,38(03):209-212.[doi:10.3760/cma.j.issn.1673-4157.2018.03.016]
 Li Jin*,Di Hongjie,Liu Chao.*.Correlation between chronic kidney disease and testosterone[J].International Journal of Endocrinology and Metabolism,2018,38(03):209-212.[doi:10.3760/cma.j.issn.1673-4157.2018.03.016]
点击复制

慢性肾脏疾病和睾酮的相关性()
分享到:

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
38
期数:
2018年03期
页码:
209-212
栏目:
基础研究
出版日期:
2018-05-20

文章信息/Info

Title:
Correlation between chronic kidney disease and testosterone
作者:
李进 狄红杰 刘超
215137 苏州市相城区太平街道卫生院糖尿病科(李进); 210028 南京中医药大学附属中西医结合医院内分泌代谢病院区(狄红杰、 刘超)
Author(s):
Li Jin* Di Hongjie Liu Chao.*
Department of Diabetes, Taiping Street Health Center of Xiangcheng District, Suzhou 215137, China
关键词:
慢性肾脏疾病 睾酮 睾酮替代治疗
Keywords:
Chronic kidney disease Testosterone Testosterone replacement therapy
DOI:
10.3760/cma.j.issn.1673-4157.2018.03.016
摘要:
睾酮水平低下是男性慢性肾脏疾病(CKD)的常见并发症之一,其机制可能与下丘脑-垂体-性腺轴功能改变、尿毒素、合并严重疾病、高龄、慢性炎性反应、营养不良等以及相关的药物影响有关。低睾酮水平可以调节血压、减轻炎性反应,可能是CKD进展期间的一种自我防卫的适应机制; 而睾酮替代治疗会上调血压、促进肾脏纤维化以及加重CKD进展。因此,睾酮水平低下被认为是CKD的标志物而非危险因素,睾酮替代治疗需要充分考虑风险/获益比
Abstract:
Low testosterone level is one of the common complications of chronic kidney disease(CKD)in men. The mechanism may be related to hypothalamic-pituitary-gonadal axis changes, uremic toxins, severe diseases, advanced age, chronic inflammation, malnutrition, and related drug effects. Low testosterone level regulates blood pressure and reduces the inflammatory response and may be a self-defending adaptation during CKD progression; testosterone replacement therapy was found to raise blood pressure, promote renal fibrosis, and aggravate CKD progression. Therefore, low testosterone is considered a marker of CKD rather than a risk factor, and testosterone replacement therapy requires careful consideration of the risk/benefit ratio.

参考文献/References:


[1] Fugl-Meyer KS,Nilsson M,Hylander B,et al. Sexual function and testosterone level in men with conservatively treated chronic kidney disease[J].Am J Mens Health,2017,11(4):1069-1076.DOI:10.1177/1557988317703207.
[2] Osman NM,Ismail AM. The impact of hemodialysis on serum prolactin and testoesrone level in CKD male patients[J].IOSR J Dent Med Sci,2016,15(1):61-65.DOI:10.9790/0853-15186165.
[3] Pampa Saico S,Teruel Briones JL,Fernández Lucas M,et al.Treatment of the testosterone deficiency in hemodialysis patients. Preliminary results[J].Nefrologia,2016,36(4):462-463.DOI:10.1016/j.nefro.2016.01.010.
[4] Dousdampanis P,Trigka K,Fourtounas C,et al.Role of testosterone in the pathogenesis, progression, prognosis and comorbidity of men with chronic kidney disease[J].Ther Apher Dial,2014,18(3):220-230.DOI:10.1111/1744-9987.12101.
[5] Kuczera P,Adamczak M,Wiecek A. Endocrine abnormalities in patients with chronic kidney disease[J].Pril(Makedon Akad Nauk Umet Odd Med Nauki),2015,36(2):109-118.DOI:10.1515/prilozi-2015-0059.
[6] Snyder G,Shoskes DA.Hypogonadism and testosterone replacement therapy in end-stage renal disease(ESRD)and transplant patients[J].Transl Androl Urol,2016,5(6):885-889.DOI:10.21037/tau.2016.08.01.
[7] Kim JM,Kim TH,Lee HH,et al.Postmenopausal hypertension and sodium sensitivity[J].J Menopausal Med,2014,20(1):1-6.DOI:10.6118/jmm.2014.20.1.1.
[8] More AS,Mishra JS,Hankins GD,et al.Prenatal testosterone exposure decreases aldosterone production but maintains normal plasma volume and increases blood pressure in adult female rats[J].Biol Reprod,2016,95(2):42.DOI:10.1095/biolreprod.116.141705.
[9] Loh SY,Salleh N.Influence of testosterone on mean arterial pressure: a physiological study in male and female normotensive WKY and hypertensive SHR rats[J].Physiol Int,2017,104(1):25-34.DOI:10.1556/2060.104.2017.1.3.
[10] Velho I,Fighera TM,Ziegelmann PK,et al. Effects of testosterone therapy on BMI, blood pressure, and laboratory profile of transgender men: a systematic review[J].Andrology,2017,5(5):881-888.DOI:10.1111/andr.12382.
[11] Sureshbabu A,Ryter SW,Choi ME.Oxidative stress and autophagy: crucial modulators of kidney injury[J].Redox Biol,2015,4:208-214.DOI:10.1016/j.redox.2015.01.001.
[12] De Miguel C,Speed JS,Kasztan M,et al.Endothelin-1 and the kidney: new perspectives and recent findings[J].Curr Opin Nephrol Hypertens,2016,25(1):35-41.DOI:10.1097/MNH.0000000000000185.
[13] Qian Q.Inflammation: a key contributor to the genesis and progression of chronic kidney disease[J].Contrib Nephrol,2017,191:72-83.DOI:10.1159/000479257.
[14] Metcalfe PD,Leslie JA,Campbell MT,et al.Testosterone exacerbates obstructive renal injury by stimulating TNF-alpha production and increasing proapoptotic and profibrotic signaling[J].Am J Physiol Endocrinol Metab,2008,294(2):E435-E443. DOI:10.1152/ajpendo.00704.2006.
[15] Nair V,Robinson-Cohen C,Smith MR,et al.Growth differentiation factor-15 and risk of CKD progression[J].J Am Soc Nephrol,2017,28(7):2233-2240. DOI:10.1681/ASN.2016080919.
[16] Feigerlová E,Battaglia-Hsu SF.IL-6 signaling in diabetic nephropathy: from pathophysiology to therapeutic perspectives[J].Cytokine Growth Factor Rev,2017,37:57-65.DOI:10.1016/j.cytogfr.2017.03.003.
[17] Neugarten J,Golestaneh L.Gender and the prevalence and progression of renal disease[J].Adv Chronic Kidney Dis,2013,20(5):390-395.DOI:10.1053/j.ackd.2013.05.004.
[18] Pippias M,Kramer A,Noordzij M,et al.The European renal association-European dialysis and transplant association registry annual report 2014: a summary[J].Clin Kidney J,2017,10(2):154-169.DOI:10.1093/ckj/sfw135.
[19] Maric C,Forsblom C,Thorn L,et al.Association between testosterone, estradiol and sex hormone binding globulin levels in men with type 1 diabetes with nephropathy[J].Steroids,2010,75(11):772-778.DOI:10.1016/j.steroids.2010.01.011.
[20] Manigrasso MB,Sawyer RT,Marbury DC,et al.Inhibition of estradiol synthesis attenuates renal injury in male streptozotocin-induced diabetic rats[J].Am J Physiol Renal Physiol,2011,301(3):F634-F640.DOI:10.1152/ajprenal.00718.2010.
[21] Beck DT,Yarrow JF,Beggs LA,et al.Influence of aromatase inhibition on the bone-protective effects of testosterone[J].J Bone Miner Res,2014,29(11):2405-2413. DOI:10.1002/jbmr.2265.
[22] Hackett G,Cole N,Saghir A,et al.Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study[J].BJU Int,2016,118(5):804-813.DOI:10.1111/bju.13516.
[23] Sinclair M,Grossmann M,Hoermann R,et al.Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone: a randomised controlled trial[J].J Hepatol,2016,65(5):906-913.DOI:10.1016/j.jhep.2016.06.007.
[24] Jung HJ,Shin HS.Effect of testosterone replacement therapy on cognitive performance and depression in men with testosterone deficiency syndrome[J].World J Mens Health,2016,34(3):194-199.DOI:10.5534/wjmh.2016.34.3.194.
[25] Almehmadi Y,Yassin AA,Nettleship JE,et al.Testosterone replacement therapy improves the health-related quality of life of men diagnosed with late-onset hypogonadism[J].Arab J Urol,2016,14(1):31-36.DOI:10.1016/j.aju.2015.10.002.
[26] Vigen R,O'Donnell CI,Barón AE,et al.Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels[J].JAMA,2013,310(17):1829-1836.DOI:10.1001/jama.2013.280386.
[27] Finkle WD,Greenland S,Ridgeway GK,et al.Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men[J].PLoS One,2014,9(1):e85805.DOI:10.1371/journal.pone.0085805.
[28] Filler G,Ramsaroop A,Stein R,et al.Is testosterone detrimental to renal function [J].Kidney Int Rep,2016,1(4):306-310.DOI:10.1016/j.ekir.2016.07.004.
[29] Lopez DS,Canfield S,Wang R.Testosterone replacement therapy and the heart: friend, foe or bystander?[J].Transl Androl Urol,2016,5(6):898-908.DOI:10.21037/tau.2016.10.02.

相似文献/References:

[1]韩菲,杨立成,孙红喜,等.2型糖尿病合并不同分期慢性肾脏疾病患者的血压特点[J].国际内分泌代谢杂志,2015,(03):149.[doi:10.3760/cma.j.issn.1673-4157.2015.03.002]
 Han Fei*,Yang Licheng,Sun Hongxi,et al.Characteristics of blood pressure in type 2 diabetic patients with different degree of chronic kidney disease[J].International Journal of Endocrinology and Metabolism,2015,(03):149.[doi:10.3760/cma.j.issn.1673-4157.2015.03.002]
[2]黄莉吉,谢绍锋,刘超.肥胖相关性肾病的研究进展[J].国际内分泌代谢杂志,2015,(03):180.[doi:10.3760/cma.j.issn.1673-4157.2015.03.010]
 Huang Liji*,Xie Shaofeng,Liu Chao..Obesity-related glomerulopathy[J].International Journal of Endocrinology and Metabolism,2015,(03):180.[doi:10.3760/cma.j.issn.1673-4157.2015.03.010]
[3]曹雯,郑仁东,曹琳,等.男性2型糖尿病患者血尿酸与性激素 相关性研究[J].国际内分泌代谢杂志,2016,36(01):28.[doi:10.3760/cma.j.issn.1673-4157.2016.01.007]
 Cao Wen,Zheng Rendong,Cao Lin,et al.Correlation between blood uric acid and sex hormones in male patients with type 2 diabetes[J].International Journal of Endocrinology and Metabolism,2016,36(03):28.[doi:10.3760/cma.j.issn.1673-4157.2016.01.007]
[4]郑仁东,刘超.糖尿病合并男性性腺功能减退症的识别与处理[J].国际内分泌代谢杂志,2016,36(06):394.[doi:10.3760/cma.j.issn.1673-4157.2016.06.09]
 Zheng Rendong,Liu Chao..Recognition and treatment of diabetes with male hypogonadism[J].International Journal of Endocrinology and Metabolism,2016,36(03):394.[doi:10.3760/cma.j.issn.1673-4157.2016.06.09]
[5]闻婷玉,康冬梅.男性睾酮与血脂代谢相关性及其机制[J].国际内分泌代谢杂志,2017,37(01):39.[doi:10.3760/cma.j.issn.1673-4157.2017.01.11]
 Wen Tingyu,Kang Dongmei..Correlation between male testosterone and blood lipid metabolism and its mechanism[J].International Journal of Endocrinology and Metabolism,2017,37(03):39.[doi:10.3760/cma.j.issn.1673-4157.2017.01.11]

备注/Memo

备注/Memo:

通信作者:狄红杰,Email:dihongjie@sina.com
更新日期/Last Update: 2018-03-30